title: Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: the good, the bad, or the evil?
authors.forename: Mads Hald
authors.initials: MH
authors.lastname: Andersen
authors.forename: Julie
authors.initials: J
authors.lastname: Gehl
authors.forename: Sine
authors.initials: S
authors.lastname: Reker
authors.forename: Poul
authors.initials: P
authors.lastname: Geertsen
authors.forename: Jürgen C
authors.initials: JC
authors.lastname: Becker
authors.forename: Per
authors.initials: P
authors.lastname: thor Stratem
mesh_terms: D018414:CD8-Positive T-Lymphocytes; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology*; D004334:Drug Administration Schedule; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines; D007376:Interleukin-2